TY - JOUR
T1 - Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method
AU - Vachon, Celine M.
AU - Murray, Josiah
AU - Allmer, Cristine
AU - Larson, Dirk
AU - Norman, Aaron D.
AU - Sinnwell, Jason P.
AU - Dispenzieri, Angela
AU - Kleinstern, Geffen
AU - Visram, Alissa
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
AU - Slager, Susan L.
AU - Kumar, Shaji K.
AU - Murray, David L.
N1 - Publisher Copyright:
© 2022 by The American Society of Hematology.
PY - 2022/6/28
Y1 - 2022/6/28
N2 - Mass-spectrometry (MS) assays detect lower levels of monoclonal proteins and result in earlier detection of monoclonal gammopathy of undetermined significance (MGUS). We examined heavy chain MGUS prevalence using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS among 3 risk groups, ages 50 or older: 327 African Americans (AA) and 1223 European Americans (EA) from a clinical biobank and 1093 unaffected first-degree relatives (FDR) of patients with hematologic disorders. Age- and sex-adjusted prevalence rates were directly standardized to 2010 United States population. Prevalence ratios were estimated for comparisons of AA and FDR to the EA group using the Poisson distribution. Results were also compared with population-based prevalence using conventional gel-based methods. Risk groups had similar sex and age distributions. MALDI-TOF MGUS prevalence was higher in the AA (16.5% [95% confidence interval (CI), 12.2%, 20.8%]) and FDR (18.3% [95% CI, 16.6%, 21.6%]) than in EA (10.8% [95% CI, 8.8%, 12.7%]), translating to prevalence ratios of 1.73 (95% CI, 1.31, 2.29) and 1.90 (95% CI, 1.55, 2.34), respectively. MALDI-TOF EA prevalence was over threefold higher than conventional estimates but showed similar age trends. Thus, the MALDI-TOF assay found greater numbers with MGUS but similar relative differences by race, family history, and age as prior studies.
AB - Mass-spectrometry (MS) assays detect lower levels of monoclonal proteins and result in earlier detection of monoclonal gammopathy of undetermined significance (MGUS). We examined heavy chain MGUS prevalence using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS among 3 risk groups, ages 50 or older: 327 African Americans (AA) and 1223 European Americans (EA) from a clinical biobank and 1093 unaffected first-degree relatives (FDR) of patients with hematologic disorders. Age- and sex-adjusted prevalence rates were directly standardized to 2010 United States population. Prevalence ratios were estimated for comparisons of AA and FDR to the EA group using the Poisson distribution. Results were also compared with population-based prevalence using conventional gel-based methods. Risk groups had similar sex and age distributions. MALDI-TOF MGUS prevalence was higher in the AA (16.5% [95% confidence interval (CI), 12.2%, 20.8%]) and FDR (18.3% [95% CI, 16.6%, 21.6%]) than in EA (10.8% [95% CI, 8.8%, 12.7%]), translating to prevalence ratios of 1.73 (95% CI, 1.31, 2.29) and 1.90 (95% CI, 1.55, 2.34), respectively. MALDI-TOF EA prevalence was over threefold higher than conventional estimates but showed similar age trends. Thus, the MALDI-TOF assay found greater numbers with MGUS but similar relative differences by race, family history, and age as prior studies.
UR - http://www.scopus.com/inward/record.url?scp=85133126265&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2021006201
DO - 10.1182/bloodadvances.2021006201
M3 - Article
C2 - 35316833
AN - SCOPUS:85133126265
SN - 2473-9529
VL - 6
SP - 3746
EP - 3750
JO - Blood Advances
JF - Blood Advances
IS - 12
ER -